Project: Arresting Wet Amd development using aganIRsen Emulsions

The project aims at validating a novel topical therapeutic approach using aganirsen (an antisense oligonucleotide) to treat wet age-related macular degeneration (AMD). Today’s standard care involves anti-VEGF agents, with costly injections every 1-3 months causing significant anguish to patients. Vision loss is averted, but only 30%-40% of AMD patients gain 3 lines in visual acuity at 2 years, and roughly every sixth patient continues losing visual acuity, progressing towards legal blindness.

Acronym	AWAIRE (Reference Number: 9350)
Duration	01/03/2015 - 01/07/2017
Project Topic	Biological Sciences / Technologies
Network	Eurostars 2
Call	Eurostars Cut-Off 2

Project partner

Number	Name	Role	Country
20389	GENE SIGNAL	Coordinator	France
20390	SEPS Pharma	Partner	Belgium